Home Healthcare IT Lung Cancer Genomic Testing Market Outlook, Growth, Report to 2030

Lung Cancer Genomic Testing Market

Lung Cancer Genomic Testing Market Size, Share & Trends Analysis Report By Type (Products, Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Fluorescence in Situ Hybridization), By Sample Type (Tissue biopsy, Liquid biopsy), By Panel Type (Multi-Gene panels, Single-Gene panels), By End-User (Research organizations, Hospitals/Clinics, Diagnostic Laboratories) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI2129DR
Study Period 2018-2030 CAGR 9%
Historical Period 2018-2020 Forecast Period 2022-2030
Base Year 2021 Base Year Market Size USD 1.38 Billion
Forecast Year 2030 Forecast Year Market Size USD 3.01 Billion
Largest Market North America Fastest Growing Market Asia Pacific
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global lung cancer genomic testing market size was valued at USD 1.38 billion in 2021. It is expected to reach USD 3.01 billion by 2030, growing at a CAGR of 9% during the forecast (2022–2030).

Cancer genomic testing is a relatively new field of genetics used to diagnose various types of cancer. Cancer genomic testing is way different from genetic testing, as all of the patient's genes are examined during genomic testing. During genomic cancer testing, gene alterations or mutations are analyzed. Initially, a patient's blood sample is required for genomic cancer testing. Cancer genomic testing assists in identifying an individual patient's cancer risk or tumor behavior. The use of genomic cancer testing to detect breast and lung cancer is in demand. When a biopsy sample is observed, it is examined to see if any genetic mutations, or changes in your genes, can be linked to the type of cancer.

Patients with lung adenocarcinoma have tumors linked to specific genetic mutations. Since some chemotherapy drugs are more effective than others in treating tumors with particular mutations, molecular analysis of your tumor, also known as genomic testing, can assist in determining which therapies are most likely beneficial to you. Non-small cell lung cancer patients are now routinely subjected to genetic testing as part of the diagnosis and staging process.

Market Dynamics

The Surge in the Number of Cancer Patients Worldwide to Favor Market Growth

It is expected that the increasing prevalence of breast and lung cancer will be the critical driver of growth in the market for genomic cancer testing during the forecast period. The rise of cancer awareness campaigns by non-governmental organizations (NGOs) contributes to expanding the market for genomic cancer testing. The development of novel cancer genomic testing techniques is receiving a dominant emphasis from major manufacturers. Increasing emphasis on research and development of lung cancer diagnostic and screening tests is another significant factor driving the market expansion.

Market Restraining Factors

Lack of Awareness to Restrict Market Growth

Screening is expensive for most people, especially those in the lower socioeconomic brackets. It's also expected that a lack of radiologists in developing and impoverished countries will limit the number of screening tests. The abovementioned issues impede the adoption of lung screening technologies, and it is anticipated that this will remain the case in the future.

Key Market Opportunities

Development of Healthcare Systems to Spur Market Opportunities

The development of healthcare structures in the direction of precision diagnostics and precision medicinal drugs will force the adoption of lung most cancer genomic testing. It can make it easier to make organizational treatment decisions and improve the overall quality of healthcare outcomes. The growing number of recommendations made by international oncology societies regarding the use of genomic testing for the analysis of lung cancers has opened many opportunities in the global market.

Regional Analysis

The global lung cancer genomic testing market is divided into North America, Europe, Latin America, and Asia-Pacific.

North America will likely dominate the global lung cancer genomic testing market, generating the most revenue. This is due to the United States abundance of research and product and service companies. Additionally, funding for research, funding advances in research, and collaboration between esteemed institutions contribute to market expansion. The Asia-Pacific region is expected to dominate the market. This is due to developments in DNA sequencing technology, an increase in life science research, and the entry of new market participants.

Report Scope

Report Metric Details
Segmentations
By Type
  1. Products
  2. Services
By Technology
  1. Polymerase Chain Reaction (PCR)
  2. Next-Generation Sequencing (NGS)
  3. Fluorescence in Situ Hybridization
By Sample Type
  1. Tissue biopsy
  2. Liquid biopsy
By Panel Type
  1. Multi-Gene panels
  2. Single-Gene panels
By End-User
  1. Research organizations
  2. Hospitals/Clinics
  3. Diagnostic Laboratories
Company Profiles QIAGEN N.V. Agilent Technologies, Inc. Thermo Fisher Scientific, Inc. Quest Diagnostics Incorporated Laboratory Corporation of America Holdings CENTOGENE N.V. BGI CeGaT GmbH Illumina, Inc. Hoffmann-La Roche Ltd. Abbott Laboratories CD Genomics NeoGenomics Laboratories Admera Health OncoDNA OPKO Health, Inc. Invitae Corporation Veracyte, Inc.
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The global lung cancer genomic testing market is segmented by type, technology, sample type, panel type, and end-user.

On the Basis of Type

Based on type, the global market is segmented into products and services. The services segment of the global lung cancer genomic testing market is anticipated to dominate. This is due to the easy availability, accessibility, and adaptability of LDTs and their lower cost compared to the IVD-dominated market for the product.

On the Basis of Technology

Based on technology, the global market is bifurcated into Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Fluorescence in Situ Hybridization. The global lung cancer genomic testing market is anticipated to be dominated by polymerase chain reaction (PCR). This is due to the overall cost-effectiveness and high sensitivity of the PCR-based genomic test for detecting lung cancer mutations that cause disease.

On the Basis of Sampling Type

Based on sampling type, the global market is segmented into Tissue biopsy and Liquid biopsy. The market is anticipated to be dominated by tissue biopsy sample types due to the standard healthcare practice of obtaining a lung tissue biopsy for lung cancer diagnosis, which is then utilized for genomic testing.

On the Basis of Panel

Based on panel, the global market is divided into Multi-Gene and Single-Gene panels. Multi-gene panels are expected to dominate the global lung cancer genomic testing market. This is due to standard healthcare practice and the familiarity of healthcare professionals with the extraction of lung tissue biopsies for lung cancer diagnosis, which are subsequently utilized for lung cancer genomic testing.

On the Basis of End-User

Based on end-user, the global market is segmented into Research organizations, Hospitals/Clinics, and Diagnostic Laboratories. The global lung cancer genomic testing market is predicted to be dominated by research organizations. This is due to the large number of clinical research and academic institutions that utilize lung cancer genomic testing for drug development, companion diagnostic development, and patient enrollment in clinical trials.

Market Size By Type

Market Size By Type
  • Products
  • Services
  • Recent Developments

    • June 2022- Tempus tied up Eli Lilly collab to bring free genomic testing to lung cancer patients.
    • May 2022- Roche partnered with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure.

    Top Key Players

    Lung Cancer Genomic Testing Market Share of Key Players

    Lung Cancer Genomic Testing Market Share of Key Players
    QIAGEN N.V. Agilent Technologies, Inc. Thermo Fisher Scientific, Inc. Quest Diagnostics Incorporated Laboratory Corporation of America Holdings CENTOGENE N.V. BGI CeGaT GmbH Illumina, Inc. Hoffmann-La Roche Ltd. Abbott Laboratories CD Genomics NeoGenomics Laboratories Admera Health OncoDNA OPKO Health, Inc. Invitae Corporation Veracyte, Inc. Others

    Frequently Asked Questions (FAQs)

    What is the estimated growth rate (CAGR) of the Lung Cancer Genomic Testing Market?
    Lung Cancer Genomic Testing Market size will grow at approx. CAGR of 9% during the forecast period.
    Some of the top prominent players in Lung Cancer Genomic Testing Market are, QIAGEN N.V., Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, CENTOGENE N.V., BGI, CeGaT GmbH, Illumina, Inc., Hoffmann-La Roche Ltd., Abbott Laboratories, CD Genomics, NeoGenomics Laboratories, Admera Health, OncoDNA, OPKO Health, Inc., Invitae Corporation, Veracyte, Inc., etc.
    North America has held a dominant position in the Lung Cancer Genomic Testing Market, with the largest market share.
    The region with the most rapid expansion in the Lung Cancer Genomic Testing Market is Asia Pacific.
    The global Lung Cancer Genomic Testing Market report is segmented as follows: By Type, By Technology, By Sample Type, By Panel Type, By End-User


    We are featured on :